Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002048
UniProt IDO15294
Primary gene name(s)OGT
Synonym gene name(s)unknown
Protein nameUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit
Protein functionCatalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in cytoplasmic and nuclear proteins resulting in their modification with a beta-linked N-acetylglucosamine, O-GlcNAc. Glycosylates a large and diverse number of proteins including histone H2B, AKT1, EZH2, PFKL, KMT2E/MLL5, MAPT/TAU and HCFC1. Can regulate their cellular processes via cross-talk between glycosylation and phosphorylation or by affecting proteolytic processing. Involved in insulin resistance in muscle and adipocyte cells via glycosylating insulin signaling components and inhibiting the 'Thr-308' phosphorylation of AKT1, enhancing IRS1 phosphorylation and attenuating insulin signaling. Involved in glycolysis regulation by mediating glycosylation of 6-phosphofructokinase PFKL, inhibiting its activity, PubMed:22923583. Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1. Plays a key role in chromatin structure by mediating O-GlcNAcylation of 'Ser-112' of histone H2B: recruited to CpG-rich transcription start sites of active genes via its interaction with TET proteins, TET1, TET2 or TET3, PubMed:22121020, PubMed:23353889. As part of the NSL complex indirectly involved in acetylation of nucleosomal histone H4 on several lysine residues, PubMed:20018852. O-GlcNAcylation of 'Ser-75' of EZH2 increases its stability, and facilitating the formation of H3K27me3 by the PRC2/EED-EZH2 complex, PubMed:24474760. Regulates circadian oscillation of the clock genes and glucose homeostasis in the liver. Stabilizes clock proteins ARNTL/BMAL1 and CLOCK through O-glycosylation, which prevents their ubiquitination and subsequent degradation. Promotes the CLOCK-ARNTL/BMAL1-mediated transcription of genes in the negative loop of the circadian clock such as PER1/2 and CRY1/2, PubMed:12150998, PubMed:18288188, PubMed:19377461, PubMed:19451179, PubMed:20018868, PubMed:20200153, PubMed:21285374, PubMed:15361863. {ECO:0000269|PubMed:12150998, ECO:0000269|PubMed:15361863, ECO:0000269|PubMed:18288188, ECO:0000269|PubMed:19377461, ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:20018852, ECO:0000269|PubMed:20018868, ECO:0000269|PubMed:20200153, ECO:0000269|PubMed:21285374, ECO:0000269|PubMed:22121020, ECO:0000269|PubMed:22923583, ECO:0000269|PubMed:23353889, ECO:0000269|PubMed:24474760}.; FUNCTION: Isoform 2: the mitochondrial isoform, mOGT is cytotoxic and triggers apoptosis in several cell types including INS1, an insulinoma cell line.
Subcellular locationIsoform 2: Mitochondrion. Membrane. Note=Associates with the mitochondrial inner membrane.;
SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus. Cell membrane. Note=Mostly in the nucleus. Retained in the nucleus via interaction with HCFC1. After insulin induction, translocated from the nucleus to the cell membrane via phophatidylinisotide binding. Colocalizes with AKT1 at the plasma membrane.;
SUBCELLULAR LOCATION: Isoform 4: Cytoplasm. Nucleus.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: O15294
Gene Ontology
(Biological Process)
Complete annatation
apoptotic process [GO:0006915];
cellular response to retinoic acid [GO:0071300];
circadian regulation of gene expression [GO:0032922];
histone H3-K4 trimethylation [GO:0080182];
histone H4-K16 acetylation [GO:0043984];
histone H4-K5 acetylation [GO:0043981];
histone H4-K8 acetylation [GO:0043982];
negative regulation of protein ubiquitination [GO:0031397];
phosphatidylinositol-mediated signaling [GO:0048015];
positive regulation of granulocyte differentiation [GO:0030854];
positive regulation of histone H3-K27 methylation [GO:0061087];
positive regulation of histone H3-K4 methylation [GO:0051571];
positive regulation of proteolysis [GO:0045862];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
protein O-linked glycosylation [GO:0006493];
regulation of gluconeogenesis involved in cellular glucose homeostasis [GO:0090526];
regulation of glycolytic process [GO:0006110];
regulation of insulin receptor signaling pathway [GO:0046626];
regulation of Rac protein signal transduction [GO:0035020];
response to insulin [GO:0032868];
response to nutrient [GO:0007584];
signal transduction [GO:0007165]
Gene Ontology
(Molecular Function)
Complete annatation
acetylglucosaminyltransferase activity [GO:0008375];
enzyme activator activity [GO:0008047];
monosaccharide binding [GO:0048029];
peptide binding [GO:0042277];
phosphatidylinositol-3,4,5-trisphosphate binding [GO:0005547];
protein N-acetylglucosaminyltransferase activity [GO:0016262];
protein O-GlcNAc transferase activity [GO:0097363]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
euchromatin [GO:0000791];
histone acetyltransferase complex [GO:0000123];
mitochondrion [GO:0005739];
MLL5-L complex [GO:0070688];
neuronal cell body [GO:0043025];
neuron projection [GO:0043005];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
plasma membrane [GO:0005886];
zymogen granule [GO:0042588]
Protein-protein interaction114049
Phylogenetic treeO15294
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.6241488506259510.06083608433840360.117223403624191
AZA vs. DISU0.02635159467811050.9170235943245150.994271142470137
AZA vs. IL7-0.214001853497180.2645193497123220.999311006273513
AZA vs. SAHA-0.1169945409004640.6304749993241620.883150743313112
DISU vs. CD30.6369837908902250.08091901689382850.157736099916924
DISU vs. IL7-0.2492083760239140.3215638637863550.702852725326852
DISU vs. SAHA-0.1415321347565170.6274819119492880.882656327700927
DMSO vs. AZA0.1159969446778030.4863595716605581
DMSO vs. CD30.7279399492189430.02508649140030230.0541056539650041
DMSO vs. DISU0.08765013974353430.7191806169094330.963064442066846
DMSO vs. IL7-0.3225652259206370.07209475252391330.511810804782874
DMSO vs. SAHA-0.2391721000177730.3091234130751180.660707227613834
HIV vs. Mock in Activation0.1078519494415570.8636656275279220.999983755607037
HIV vs. Mock in Latency0.1114949861443730.4979145738050250.999834320637052
IL7 vs. CD30.4174476139068080.1971457590153750.319215600562762
SAHA vs. CD30.4833614082567480.1781066399369180.276195417148523
SAHA vs. IL70.09327442538148050.7012430784557840.861775490350765
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.114123 0.508907
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.917 0.848 0.669 0.707 0.948
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1W3B X-ray 2.8Å A/B=26-410.
3PE3 X-ray 2.7Å A/B/C/D=323-1041.
3PE4 X-ray 1.9Å A/C=323-1041.
3TAX X-ray 1.8Å A/C=323-1041.
4AY5 X-ray 3.1Å A/B/C/D=323-1041.
4AY6 X-ray 3.3Å A/B/C/D=323-1041.
4CDR X-ray 3.1Å A/B/C/D=323-1041.
4GYW X-ray 1.7Å A/C=323-1041.
4GYY X-ray 1.8Å A/C=323-1041.
4GZ3 X-ray 1.9Å A/C=323-1041.
4GZ5 X-ray 3.0Å A/B/C/D=323-1041.
4GZ6 X-ray 2.9Å A/B/C/D=323-1041.
4N39 X-ray 1.7Å A=323-1041.
4N3A X-ray 1.8Å A=323-1041.
4N3B X-ray 2.1Å A=323-1041.
4N3C X-ray 2.5Å A=323-1041.
4XI9 X-ray 3.1Å A/B/C/D=323-1041.
4XIF X-ray 3.2Å A/B/C/D=323-1041.
5BNW X-ray 2.4Å A=323-1041.
5C1D X-ray 2.0Å A=323-1041.
5HGV X-ray 2.0Å A/C=323-1041.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00514 Other types of O-glycan biosynthesis - Homo sapiens (human)
hsa04931 Insulin resistance - Homo sapiens (human)